Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?

Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder, a Prospective, Randomized Pilot Study With Wait List as Control Group.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00202709

Enrollment

Registered

2005-09-20

Start date

2002-05-31

Completion date

2003-08-31

Last updated

2011-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Agoraphobia, PTSD, Social Phobia

Keywords

Anxiety disorder, Thought Field Therapy, Psychotherapy, Agoraphobia, Social Phobia, Post Traumatic Stress Disorder

Brief summary

The purpose of this study is to find out if Thought Field Therapy has effect on certain anxiety disorders; agoraphobia, social phobia, and post traumatic stress disorder (PTSD).

Detailed description

Thought Field Therapy is an alternative treatment method that has been shown, by casuistic reports, to give good results when applied for anxiety disorders. In this study 52 patients, with one or more of the diagnoses agoraphobia, social phobia and/or PTSD, where randomized to either treatment with TFT or a wait list. The treatment group all got treatment in one week. 2 1/2 months later both the treatment group and the control group were tested on the same items as before the treatment started. After this evaluation phase the control group got the same treatment as the treatment or study group. Both groups were evaluated 3 and 12 months after treatment, the study group also 6 months after treatment. 4 patients were omitted because they changed groups. The study were performed from May 2002 until June 2003.

Interventions

BEHAVIORALThought Field Therapy (TFT)

Treatment with TFT twice in one week

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* One or more of the study diagnoses agoraphobia, social phobia and/or PTSD

Exclusion criteria

* Ongoing psychosis * Ongoing serious drug problems

Design outcomes

Primary

Measure	Time frame
Global symptom index (gsi) on the Symptom checklist 90 revised (SCL-90-R)	Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.

Secondary

Measure	Time frame
Davidson Trauma Scale	Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
Liebowitz Social Anxiety Scale	Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
Hospital Anxiety and Depression Scale (HADS)	Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
Fear Questionnaire (FQ)	Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
Sheehan Disability Scale	Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026